KMO and Huntington disease: For instance, the KMO inhibitor CHDI-340246 potently and dose-dependently modulates the KP in transgenic Huntington’s disease models, inhibiting the formation of 3-HK and QUIN while elevating neuroprotective KYNA levels in the brain (Kudo et al., 2024; Tufail et al., 2024).